QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orrick, J. J Articles by Steinhart, C. R Search for Related Content PubMed PubMed Citation Articles by Orrick, J. J Articles by Steinhart, C. R

FORMULARY FORUM

Atazanavir

Clinical Assistant Professor, Colleges of Nursing and Pharmacy, University of Florida, Gainesville, FL

Corklin R Steinhart, MD PhD

Senior Attending Physician, Mercy Hospital; Steinhart Medical Associates, Miami, FL

Reprints: Joanne J Orrick PharmD BCPS, College of Pharmacy, University of Florida, Box 100187, Gainesville, FL 32610-0187, orricjj{at}ufl.edu

OBJECTIVE: To review the pharmacology, virology, pharmacokinetics, resistance profile, clinical efficacy, safety, and drug interactions of atazanavir.

DATA SOURCES: A PubMed and NLMGateway search (1966–June 2004) utilizing the key words atazanavir and BMS-232632 was performed. Abstracts from scientific meetings, including the Conference on Retroviruses and Opportunistic Infections, International AIDS Society Conference on HIV Pathogenesis and Treatment, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Infectious Diseases Society of America, were also reviewed.

STUDY SELECTION AND DATA EXTRACTION: All publications and meeting abstracts were reviewed, and information relevant to the formulary decision-making process was selected.

DATA SYNTHESIS: Atazanavir is a once-daily protease inhibitor (PI) that received approval by the Food and Drug Administration in June 2003. In clinical trials in antiretroviral (ARV)-naïve patients, atazanavir had efficacy similar to that of efavirenz or nelfinavir. In ARV-experienced patients, atazanavir was inferior to lopinavir/ritonavir unless atazanavir was coadministered with low-dose ritonavir. Following failure of an atazanavir-containing regimen in ARV-naïve patients, a unique 150L mutation was seen. Atazanavir resistance is likely when resistance to 3 PIs is present. Atazanavir can cause increases in unconjugated bilirubin levels, which rarely leads to jaundice or scleral icterus. In contrast to comparators, atazanavir did not negatively impact the lipid profile. Similar to other PIs, atazanavir is metabolized by and inhibits CYP3A at clinically relevant concentrations; therefore, many potential drug interactions exist.

CONCLUSIONS: Atazanavir is a once-daily PI that, unlike other PIs, does not negatively impact the lipid profile. Atazanavir may be particularly desirable in patients with hyperlipidemia or other coronary artery disease risk factors.

Key Words: atazanavir, BMS-232632, Reyataz

Published Online, September 7, 2004. www.theannals.com, DOI 10.1345/aph.1D394

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-029-H02

This article has been cited by other articles:

				J. Borras-Blasco, A. Navarro-Ruiz, C. Borras, and E. Castera Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection J. Antimicrob. Chemother., November 1, 2008; 62(5): 879 - 888. [Abstract] [Full Text] [PDF]

				H. Zhou, E. C. Gurley, S. Jarujaron, H. Ding, Y. Fang, Z. Xu, W. M. Pandak Jr., and P. B. Hylemon HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1071 - G1080. [Abstract] [Full Text] [PDF]

				S. A. Krikorian and D. C. Rudorf Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know? Journal of Pharmacy Practice, August 1, 2005; 18(4): 278 - 294. [Abstract] [PDF]

				E. S. Perloff, S. X. Duan, P. R. Skolnik, D. J. Greenblatt, and L. L. von Moltke ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO Drug Metab. Dispos., June 1, 2005; 33(6): 764 - 770. [Abstract] [Full Text] [PDF]